Medtronic PLC · Q1 2025 earnings

Briefing

Product innovation drove growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation.

Medtronic reported Q1 worldwide revenue of $7.915 billion, an increase of 2.8% as reported and 5.3% on an organic basis. GAAP diluted earnings per share (EPS) were $0.80; non-GAAP diluted EPS of $1.23. The company raised its FY25 organic revenue growth guidance to 4.5% to 5% and diluted non-GAAP EPS guidance to the new range of $5.42 to $5.50.

• Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organic
• GAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23
• Company increases FY25 organic revenue growth and EPS guidance
• Multiple franchises delivering, with growth acceleration in Cardiac Ablation Solutions and Neuromodulation and continued strength in Spine, Structural Heart, and Diabetes

Headline financials

Revenue & EPS history

The company raised its FY25 organic revenue growth guidance to 4.5% to 5% versus the prior range of 4% to 5%. The company raised its FY25 diluted non-GAAP EPS guidance to the new range of $5.42 to $5.50 versus the prior $5.40 to $5.50. This includes an estimated -5% impact from foreign currency exchange based on recent rates, unchanged from the prior guidance.